Medulloblastoma Drug Market Report 2026

The medulloblastoma drug market size has grown strongly in recent years. It will grow from $3.03 billion in 2025 to $3.28 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to advances in pediatric oncology, increased brain tumor diagnosis, chemotherapy protocol standardization, expansion of cancer hospitals, improved surgical outcomes.

The medulloblastoma drug market size is expected to see strong growth in the next few years. It will grow to $4.49 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to growth in targeted brain cancer research, increasing survival rates, rising pediatric oncology investment, expansion of specialty centers, growth in rare disease funding. Major trends in the forecast period include rising use of combination chemotherapy regimens, growing focus on pediatric oncology care, increasing clinical trial activity for rare brain tumors, expansion of hospital-based cancer treatment, increased research into targeted brain cancer therapies.

The increasing prevalence of brain tumors is anticipated to fuel expansion in the medulloblastoma drug market. A brain tumor involves the abnormal cell growth within the brain or spinal canal, which may be benign or malignant and can impair brain function. This rise stems from improved detection methods, an aging demographic, environmental influences, greater public awareness, and genetic factors. Medulloblastoma treatments, such as chemotherapy, radiation, and targeted therapies, work by reducing tumor size, eliminating cancer cells, and halting their proliferation. For instance, in January 2025, the American Cancer Society - a US-based non-profit dedicated to cancer research and patient support - reported an estimated 14,040 new cases of brain tumors and other nervous system cancers in males and 10,780 in females for 2025, with a total of 18,330 projected deaths. Thus, the growing incidence of brain tumors is propelling the medulloblastoma drug market forward.

The growing emphasis on personalized medicine is set to fuel expansion in the medulloblastoma drug market. Personalized medicine involves customizing treatments and healthcare plans to match each patient's unique traits, genetics, and requirements. This trend stems from progress in genomics, biotechnology, and data analytics, enabling therapies tailored to individual genetic makeup and personal health information. The heightened focus on personalized medicine bolsters the medulloblastoma drug market by boosting demand for precision therapies, enhancing treatment outcomes, reducing side effects, and improving patient survival. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit, reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, compared to six in 2022. Among these 2023 approvals, seven targeted cancers and three addressed other conditions. Thus, the rising adoption of personalized medicine continues to propel growth in the medulloblastoma drug market.

The escalating healthcare spending is projected to boost the medulloblastoma drug market in the years ahead. Healthcare spending encompasses all expenditures on medical services, drugs, preventive measures, facilities, and administrative expenses by governments, private organizations, and individuals. This rise stems from elements like an aging demographic, progress in medical innovations, the growing burden of chronic conditions, and rising administrative expenses. Such spending supports medulloblastoma drug development through investments in research, clinical studies, and cutting-edge therapies, fostering medical advancements and targeted care for rare conditions. For instance, in December 2024, the Centers for Medicare & Medicaid Services - a U.S. federal agency - reported that hospital spending surged 10.4% to $1.51 trillion in 2023, outpacing the 3.2% rise from 2022, while prescription drug costs climbed 11.4% to $449.7 billion, exceeding the 7.8% increase seen in 2022. Thus, increasing healthcare spending is fueling expansion in the medulloblastoma drug market.

Major companies operating in the medulloblastoma drug market are Pfizer Inc., Novartis AG, Roche Holding AG, Bristol-Myers Squibb Company, Merck & Co. Inc., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Sanofi S.A., Bayer AG, Eisai Co. Ltd., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ipsen S.A., Daiichi Sankyo Co. Ltd., Jazz Pharmaceuticals plc, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Curtana Pharmaceuticals Inc., Biodexa Pharmaceuticals plc.

North America was the largest region in the medulloblastoma drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medulloblastoma drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medulloblastoma drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of imported chemotherapy agents and investigational drugs used in medulloblastoma treatment across pediatric and adult oncology settings. The impact is strongest in hospital pharmacies and specialty cancer centers, where access to advanced therapies is critical. Regions such as North America and Europe have experienced higher input costs due to dependence on cross border oncology drug supply chains. Rising tariff related expenses have influenced treatment pricing, procurement planning, and inventory management in specialized care settings. Conversely, tariffs have encouraged local drug manufacturing, expanded regional production capacity, and greater supply diversification over the long term.

The medulloblastoma drug market research report is one of a series of new reports that provides medulloblastoma drug market statistics, including medulloblastoma drug industry global market size, regional shares, competitors with a medulloblastoma drug market share, detailed medulloblastoma drug market segments, market trends and opportunities, and any further data you may need to thrive in the medulloblastoma drug industry. This medulloblastoma drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Medulloblastoma drugs treat medulloblastoma, a rapidly growing brain tumor that starts in the cerebellum or posterior fossa, commonly affecting children. Treatment usually combines surgery, radiation therapy, and chemotherapy. These medications target the tumor and mainly consist of chemotherapy agents.

The primary types of medulloblastoma drugs include dianhydrogalactitol, investigational medicinal product 5471, ipilimumab, indoximod, and additional options. Dianhydrogalactitol serves as an alkylating agent in cancer therapy, including for medulloblastoma, by disrupting cancer cell DNA to halt cell division and growth. It encompasses various forms, such as chemotherapy agents, targeted therapies, and radiation treatments, delivered via intravenous, oral, or intrathecal methods. Distribution occurs through hospital pharmacies, online pharmacies, and retail pharmacies, serving diverse end users like hospitals, home care settings, specialty centers, and more.

The medulloblastoma drug market consists of sales of chemotherapy drugs, targeted therapies, supportive care medications, steroids, and topoisomerase inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.